Drug intelligence / Profile preview

HN001 + M-16V + CECT5716

Development stage: Unknown
Lead developer: Fonterra
Modality: Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
Administration: Oral

Overview

This is a combination probiotic product containing three well-characterized strains: Lactobacillus rhamnosus HN001, Bifidobacterium breve M-16V, and Lactobacillus fermentum CECT5716. Each strain has been isolated from natural sources (HN001 from cheddar cheese, M-16V from infant gut, and CECT5716 from human breast milk) and is recognized for its safety in food applications. These probiotics are used to support digestive health, modulate the gut microbiota, enhance immune function in infants and children, and may help prevent or reduce the risk of conditions such as eczema (atopic dermatitis) and necrotizing enterocolitis in preterm infants. The mechanism of action involves colonization of the gastrointestinal tract by beneficial bacteria that outcompete pathogens, modulate immune responses (including Toll-like receptor signaling), suppress inflammation, and promote a healthy balance of intestinal flora[1][3][5][6].

Other names: 益生菌鼠李糖乳杆菌HN001 + 短双歧杆菌M-16V + 发酵乳杆菌CECT5716

Beyond the preview

Go deeper on HN001 + M-16V + CECT5716.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HN001 + M-16V + CECT5716.

Explore the full profile